ISEE vs. ZLAB, XENE, INSP, ELAN, ASND, BRBR, IMVT, ENSG, ABCM, and ITCI
Should you be buying IVERIC bio stock or one of its competitors? The main competitors of IVERIC bio include Zai Lab (ZLAB), Xenon Pharmaceuticals (XENE), Inspire Medical Systems (INSP), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), BellRing Brands (BRBR), Immunovant (IMVT), The Ensign Group (ENSG), Abcam (ABCM), and Intra-Cellular Therapies (ITCI). These companies are all part of the "medical" sector.
Zai Lab (NASDAQ:ZLAB) and IVERIC bio (NASDAQ:ISEE) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership.
Zai Lab presently has a consensus price target of $83.10, suggesting a potential upside of 248.72%. IVERIC bio has a consensus price target of $25.75, suggesting a potential downside of 35.54%. Given IVERIC bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Zai Lab is more favorable than IVERIC bio.
IVERIC bio has a net margin of 0.00% compared to IVERIC bio's net margin of -156.07%. IVERIC bio's return on equity of -38.48% beat Zai Lab's return on equity.
Zai Lab has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, IVERIC bio has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.
IVERIC bio has lower revenue, but higher earnings than Zai Lab. IVERIC bio is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zai Lab had 1 more articles in the media than IVERIC bio. MarketBeat recorded 1 mentions for Zai Lab and 0 mentions for IVERIC bio. IVERIC bio's average media sentiment score of 1.87 beat Zai Lab's score of 0.45 indicating that Zai Lab is being referred to more favorably in the media.
Zai Lab received 153 more outperform votes than IVERIC bio when rated by MarketBeat users. Likewise, 62.50% of users gave Zai Lab an outperform vote while only 42.86% of users gave IVERIC bio an outperform vote.
43.7% of Zai Lab shares are held by institutional investors. 5.2% of Zai Lab shares are held by company insiders. Comparatively, 2.7% of IVERIC bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Zai Lab beats IVERIC bio on 14 of the 17 factors compared between the two stocks.
Get IVERIC bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ISEE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ISEE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
IVERIC bio Competitors List
Related Companies and Tools